Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Interest & Investment Income (2016 - 2025)

Capricor Therapeutics has reported Interest & Investment Income over the past 15 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $2.0 million for Q4 2025, up 194.39% from a year ago — trailing twelve months through Dec 2025 was $6.3 million (up 184.05% YoY), and the annual figure for FY2025 was $6.3 million, up 184.05%.
  • Interest & Investment Income for Q4 2025 was $2.0 million at Capricor Therapeutics, up from $1.7 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CAPR hit a ceiling of $2.0 million in Q4 2025 and a floor of $9165.0 in Q1 2021.
  • Median Interest & Investment Income over the past 5 years was $434320.5 (2023), compared with a mean of $538414.6.
  • Biggest five-year swings in Interest & Investment Income: plummeted 59.61% in 2021 and later skyrocketed 2998.53% in 2023.
  • Capricor Therapeutics' Interest & Investment Income stood at $15984.0 in 2021, then surged by 2275.49% to $379699.0 in 2022, then increased by 19.09% to $452199.0 in 2023, then skyrocketed by 51.83% to $686572.0 in 2024, then skyrocketed by 194.39% to $2.0 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.0 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.